- The study examined gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML) patients, focusing on how these mutations influence clinical characteristics and patient outcomes.
- Among 151 newly diagnosed CN-AML patients, 36.42% tested positive for specific mutations, with 74.55% of them having additional co-mutations. The most frequent mutated genes included various transcription factors and signaling pathways.
- Results indicated that patients with certain gene mutations had distinct clinical features, such as lower platelet counts and higher proportions of bone marrow blasts, suggesting that these genetic variations could play a significant role in prognosis and treatment approaches.